AMBULERO
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.
AMBULERO
Industry:
Biotechnology Genetics Life Science Therapeutics
Founded:
2019-01-01
Address:
Miami, Florida, United States
Country:
United States
Website Url:
http://www.ambulero.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
5.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Google GStatic Google Static Content
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Investors List
Orphinic Scientific
Orphinic Scientific investment in Seed Round - Ambulero
Official Site Inspections
http://www.ambulero.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Ambulero"
Home | Ambulero
Jul 22, 2024 Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. Our cell therapy program uses stromal cells engineered to express a cell adhesion …See details»
Ambulero - Crunchbase Company Profile & Funding
Organization. Ambulero . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Ambulero is a cell …See details»
Board and Advisors | Ambulero
30 years of experience in the healthcare industry, advancing pharmaceuticals and biologics to market including over 20 US & foreign products. Early in his career, Dr. Anderson was a professional baseball player with the Pittsburgh Pirates; …See details»
Investors and Development | Ambulero
Ambulero will file an IND for our lead gene therapy product AMB-301 by late 2024. INVESTORS AND DEVELOPMENT. Ambulero is a pioneer in the use of gene and cell therapy approaches …See details»
Ambulero 2025 Company Profile: Valuation, Funding
Ambulero General Information Description. Operator of a biotechnology company intended to develop new ways to treat vascular tissue disease. The company …See details»
Ambulero - Funding, Financials, Valuation & Investors - Crunchbase
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. New. Resources. ... How much funding has this …See details»
Ambulero - Company Profile - Tracxn
Ambulero - Developer of cell & gene therapies for the treatment of rare vascular disease and critical limb ischemia. Raised a total funding of $5.5M over 2 rounds from 2 investors. Founded …See details»
Ambulero - The Org
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. A platform company that can deliver the adhesion …See details»
Ambulero - Contacts, Employees, Board Members, Advisors
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. ... Experience the new Crunchbase, powered by AI . …See details»
Ambulero | VentureRadar
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. ? Our cell therapy program uses stromal cells …See details»
Ambulero - Org chart - The Org
Explore Ambulero's organizational chart. Discover current team members including executives, board members, and advisors.See details»
Ambulero - Company Profile & Staff Directory - ContactOut
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can deliver the adhesion …See details»
Ambulero - app.biopharmiq.com
About: Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can …See details»
Ambulero Overview | SignalHire Company Profile
Ambulero is a private company that has been in the industry for 4 years. The company currently specializes in the Biotechnology area. The position of the CEO is occupied by Robert L …See details»
AB - Orphinic Scientific
Ambulero received an exclusive worldwide license to Dr Velazquez’s and Dr Liu’s innovations from the University of Miami. Ambuleros’ mission is to develop a pipeline of new gene therapy …See details»
Investors and Development | Ambulero
Ambulero will file an IND for our lead gene therapy product AMB-301 by late 2024. INVESTORS AND DEVELOPMENT. Ambulero is a pioneer in the use of gene and cell therapy approaches …See details»
Media Center - Ambulero
Apr 18, 2024 Ambulero announces expansion of its Scientific Advisory Board with the addition of Tim Kelly, Ind ustry Leader in AAV Technology Ambulero is a first-in-class gene & cell therapy …See details»
Ambulero - Longevity List
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can deliver the adhesion …See details»
Ambulero’s Investigational Gene Therapy to Treat Vascular Disease ...
Jun 12, 2023 Ambulero is developing a first-in-class gene and cell therapy platform for treating serious vascular diseases and nonhealing wounds where amputation is a care option. …See details»
Pipeline - Ambulero
We estimate that roughly 2 million people in the US have CLI and about 5-10% will have an amputation as part of their care. Ambulero is working with outside research organizations to …See details»